Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synergistic Interactions Between the Quinolone-Derived Compound HT61 and Tobramycin Against a Range of Clinical Isolates of Pseudomonas aeruginosa In Vitro.

Lung·2025
Same author

"HRCT predictors of GGO surgical resection: Histopathological and molecular correlation in the era of lung sparing surgery".

Lung cancer (Amsterdam, Netherlands)·2022
Same author

A novel murine model of pulmonary fibrosis: the role of platelets in chronic changes induced by bleomycin.

Journal of pharmacological and toxicological methods·2021
Same author

The small quinolone derived compound HT61 enhances the effect of tobramycin against Pseudomonas aeruginosa in vitro and in vivo.

Pulmonary pharmacology & therapeutics·2019
Same author

Pharmacology and Therapeutics of Bronchodilators Revisited.

Pharmacological reviews·2019
Same author

Radiolabelling and immunohistochemistry reveal platelet recruitment into lungs and platelet migration into airspaces following LPS inhalation in mice.

Journal of pharmacological and toxicological methods·2019

Related Experiment Video

Updated: Jul 7, 2026

In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

Adenosine receptors and asthma.

R A Brown1, D Spina, C P Page

  • 1King's College London, Sackler Institute of Pulmonary Pharmacology, Division of Biomedical and Health Sciences, London, UK.

British Journal of Pharmacology
|March 4, 2008
PubMed
Summary

Adenosine receptors are being investigated as asthma therapeutics. Targeting specific adenosine receptor subtypes, like A(1), A(2A), A(2B), and A(3), shows promise for novel asthma treatments.

Area of Science:

  • Pharmacology
  • Respiratory Medicine
  • Immunology

Background:

  • Adenosine plays a significant role in asthma pathogenesis.
  • All adenosine receptor subtypes are being explored as potential therapeutic targets for asthma.

Purpose of the Study:

  • To review the current understanding of adenosine receptor subtypes in asthma.
  • To evaluate the therapeutic potential of targeting adenosine receptors for asthma treatment.

Main Methods:

  • Preclinical investigations of selective A(1) receptor antagonists.
  • Clinical development of selective A(2A) receptor agonists.
  • Research into A(2B) receptor antagonists and their effects on inflammatory cells.
  • Exploration of A(3) receptor ligands for anti-inflammatory effects.

More Related Videos

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Related Experiment Videos

Last Updated: Jul 7, 2026

In vitro Measurements of Tracheal Constriction Using Mice
10:20

In vitro Measurements of Tracheal Constriction Using Mice

Published on: June 25, 2012

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Main Results:

  • A(1) receptor antagonists show preclinical promise for asthma symptoms like bronchoconstriction and inflammation.
  • A(2A) receptor agonists are in clinical trials, but initial efficacy reports are inconclusive.
  • A(2B) receptor antagonists demonstrate potential in preclinical models by inhibiting mast cell activation and other pro-inflammatory effects.
  • The role of A(3) receptor ligands is still under investigation, with conflicting reports on their anti-inflammatory effects.

Conclusions:

  • Targeting adenosine receptors offers a promising avenue for novel asthma therapeutics.
  • Further research is needed to establish the precise role of each adenosine receptor subtype in asthma and to develop effective, subtype-selective treatments.